Please login to the form below
tucatinib
This page shows the latest tucatinib news and features for those working in and with pharma, biotech and healthcare.
Merck signs separate agreements with Seattle Genetics for two cancer drugs
In a separate agreement, Seattle Genetics has granted Merck an exclusive license to commercialise Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, in Asia, the Middle East, Latin America and other
Latest news
-
Seattle Genetics wins FDA priority review for oral HER2 drug
Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... If Seattle does gain approval for tucatinib, it will go on to compete with rival HER2 inhibitor Enhertu, marketed by
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
-
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
Also on the horizon is Seattle Genetics’ oral HER2 drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus Roche’s chemotherapy Xeloda (capecitabine) ... HER2CLIMB-02 will compare tucatinib to placebo in
-
AZ, Daiichi Sankyo strengthen case for HER2 candidate
Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active HER2 inhibitor tucatinib.
-
Seattle Genetics preps filing next year for oral HER2 drug
metastases. The company has already started a phase 3 trial that aims to support earlier use of tucatinib. ... HER2CLIMB-02 will compare tucatinib to placebo in combination with Kadcyla in HER2-positive breast cancer patients who have received prior
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
